본문 바로가기
KERD
논문KCI 등재

간암 한약제제 임상시험 가이드라인 개발을 위한 한약제제 무작위배정 대조군 임상시험 고찰

Analysis of Existing Guidelines and Randomized, Controlled, Clinical Trials for Development of [Guideline of Clinical Trial on Herbal Medicinal Product for Liver Cancer]

김동훈|박은주|성신|김성수|한가진|임정태
대한한방내과학회 (The Society Of Korean Oriental Internal Medicine)|2019.03|대한한방내과학회지 (The Journal of Korean Oriental Internal Medicine)|제40권 제1호|pp. 89-116|DOI https://doi.org/10.22246/jikm.2019.40.1.89

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

clinical trialguidelinehepatocellular carcinomaliver neoplasmsherbal medicinal product
주제분류한의학

초록

Objective: This study aimed to ascertain what should be considered in the “Guideline for Clinical Trials with Herbal Medicinal Products for Liver Cancer,” by analyzing existing guidelines and clinical trials. Methods: Committee for the development of a guideline, consisting of 6 Korean medicine doctors, reviewed guidelines and clinical trials on using herbal medicine for treating liver cancer. The trials were analyzed in terms of inclusion and exclusion of participants, intervention, comparators, outcomes, and trial design. We then compared the results of our analysis with the guidelines to identify issues we must to consider when following the “Guideline for Clinical Trials with Herbal Medicinal Products for Liver Cancer.” Several guidelines for antitumor agents and clinical trials on herbal medicine were obtained from the Ministry of Food and Drug Safety homepage, etc. The search terms were as follows: “liver neoplasms”; “herbal medicine”; “medicine, Korean traditional”; and “medicine, Chinese Traditional.”. Results: Ten articles were obtained from pubmed and Embase. There was no guideline for clinical trials on using herbal medicine for treating liver cancer. All the participants in the reviewed articles had primary liver cancer, and the type of intervention varied (e.g., decoction, patches, and capsules. The comparators included placebos and conventional treatments such as chemotherapy. The outcome assessment methods were tumor response, quality of life, survival, and liver function tests. Adverse events occuring during the trial were also evaluated. Conclusion: Findings were derived by reviewing existing guidelines and comparing them with clinical trials on liver cancer and herbal medicinal products. These results will be utilized in the development of the “Guideline for Clinical Trials with Herbal Medicinal Products for Liver Cancer.”

Abstract

Objective: This study aimed to ascertain what should be considered in the “Guideline for Clinical Trials with Herbal Medicinal Products for Liver Cancer,” by analyzing existing guidelines and clinical trials. Methods: Committee for the development of a guideline, consisting of 6 Korean medicine doctors, reviewed guidelines and clinical trials on using herbal medicine for treating liver cancer. The trials were analyzed in terms of inclusion and exclusion of participants, intervention, comparators, outcomes, and trial design. We then compared the results of our analysis with the guidelines to identify issues we must to consider when following the “Guideline for Clinical Trials with Herbal Medicinal Products for Liver Cancer.” Several guidelines for antitumor agents and clinical trials on herbal medicine were obtained from the Ministry of Food and Drug Safety homepage, etc. The search terms were as follows: “liver neoplasms”; “herbal medicine”; “medicine, Korean traditional”; and “medicine, Chinese Traditional.”. Results: Ten articles were obtained from pubmed and Embase. There was no guideline for clinical trials on using herbal medicine for treating liver cancer. All the participants in the reviewed articles had primary liver cancer, and the type of intervention varied (e.g., decoction, patches, and capsules. The comparators included placebos and conventional treatments such as chemotherapy. The outcome assessment methods were tumor response, quality of life, survival, and liver function tests. Adverse events occuring during the trial were also evaluated. Conclusion: Findings were derived by reviewing existing guidelines and comparing them with clinical trials on liver cancer and herbal medicinal products. These results will be utilized in the development of the “Guideline for Clinical Trials with Herbal Medicinal Products for Liver Cancer.”

참고문헌 (74)

  1. Lee HS, "Oncology", pp.339~ (2012), Iljogak
  2. "Global Cancer Observatory" (2019)[URL]
  3. Wallace MC, "The evolving epidemiology of hepatocellular carcinoma:a global perspective", Expert Rev Gastroenterol Hepatol, 9(6), pp.765~779 (2015)
  4. "National Center Information Cancer" (2019)[URL]
  5. "Korean Statistical Information Service"[URL]
  6. Park JW, "National project for Early screening of Liver cancer", Clin Mol Hepatol, 8(3), pp.16~19 (2002)
  7. "Plymouth Meeting" (2019)[URL]
  8. Committee of Korean Clinical Practice Guideline for Hepatocellular carcinoma, "Practice Guidelines for Management of Hepatocellular Carcinoma", The Korean Liver Cancer Association and National Cancer Center, ~ (2018)
  9. Minagawa M, "Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma", Ann Surg, 238(5), pp.703~710 (2003)
  10. Park JW, "Global patterns of hepatocellular carcinoma management from diagnosis to death : the BRIDGE Study", Liver Int, 35(9), pp.2155~2166 (2015)
  11. Yoo SH, "Complications Associated with Transcatheter Arterial Chemoembolization in Patients with Hepatocellular Carcinoma", Korean J of liver cancer study group, 11(2), pp.144~148 (2011)
  12. Llovet JM, "Design and endpoints of clinical trials in hepatocellular carcinoma", J Natl Cancer Inst, 100(10), pp.698~711 (2008)
  13. Thomas MB, "Systemic therapy for hepatocellular carcinoma", Cancer Journal, 14(2), pp.123~127 (2008)
  14. Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359(4), pp.378~390 (2008)
  15. Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double-blind, placebo-controlled trial", Lancet Oncol, 10(1), pp.25~34 (2009)
  16. Cheng AL, "Sunitinib versus sorafenib in advanced hepatocellular cancer : results of a randomized phase III trial", J Clin Oncol, 31(32), pp.4067~4075 (2013)
  17. Cainap C, "Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma : results of a randomized phase III trial", J Clin Oncol, 33(2), pp.172~179 (2015)
  18. Bruix J, "Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma : subanalyses of a phase III trial", J Hepatol, 57(4), pp.821~829 (2012)
  19. Raoul JL, "Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function : SHARP trial subanalyses", J Hepatol, 56(5), pp.1080~1088 (2012)
  20. Llovet JM, "Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma", Clin Cancer Res, 18(8), pp.2290~2300 (2012)
  21. Bruix J, "Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE) : a randomised, double blind, placebo-controlled, phase 3 trial", Lancet, 389(10064), pp.56~66 (2017)
  22. El-Khoueiry AB, "Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040) : an open-label, non-comparative, phase 1", 2 dose escalation and expansion trial, 2017, pp.389(10088), 2492~2502
  23. 김보현, "Systemic Therapy for Advanced Hepatocellular Carcinoma: Targeted Therapy and Immunotherapy", Journal of Liver Cancer, 18(1), pp.17~22 (2018), 대한간암학회[DOI]
  24. Michot JM, "Immune- related adverse events with immune checkpoint blockade:a comprehensive review", Eur J Cancer, 54, pp.139~148 (2016)
  25. Bourke JM, "Management of adverse events related to new cancer immunotherapy(immune checkpoint inhibitors)", Med J Aust, 205(9), pp.418~424 (2016)
  26. Wang S, "Application of Traditional Chinese Medicines as personalized therapy in human cancers", Am J Chin Med, 46(5), pp.953~970 (2018)
  27. 한가진, "위암 한약제제 임상시험 가이드라인 개발을 위한 한약제제 무작위배정 대조군 임상시험 고찰", 대한한의학회지, 38(3), pp.124~142 (2017), 대한한의학회[DOI]
  28. Ruan WJ, "Anticancer effects of Chinese herbal medicine, science or myth?", J Zhejiang Univ Sci B, 7(12), pp.1006~1014 (2006)
  29. 김경석, "肺癌의 한방치료 임상연구 방법론", 대한한의학원전학회지, 23(4), pp.39~62 (2010), 대한한의학원전학회
  30. Hong SH, "Clinical Practice Guidelines of Korean Medicine for Hepatocellular Carcinoma", J of Kor Traditional Oncology, 20(1), pp.55~79 (2015)
  31. 김성훈, "천연물 항암제제 임상시험 평가지표 개발연구", 동의생리병리학회지, 20(6), pp.1678~1727 (2006), 한의병리학회
  32. Ministry of Food and Drug Safety, "Guideline for evaluation of clinical trial of anticancer drugs", ~
  33. National Institute of Food and Drug Safety Evaluation, "Guidelines for clinical testing of anti-cancer drugs and non-clinical test data for approval of items", ~ (2010)
  34. National Institute of Food and Drug Safety Evaluation, "Guidelines for clinical trial of anti-cancer drugs", ~ (2015)
  35. National Institute of Food and Drug Safety Evaluation, "Guidelines for non-clinical trial of anti-cancer drugs", ~ (2012)
  36. National Institute of Food and Drug Safety Evaluation, "Guidelines for Exemption of Anticancer Drug Data in Bridging Study", ~ (2015)
  37. Ministry of Food and Drug Safety, "Guideline for the use of clinical trial medicines for therapeutic purposes", ~ (2018)
  38. Kim CM, "Recommendations for Early Screening of Liver Cancer", Korean Association for the Study of the Liver and National Cancer Center, ~ (2001)
  39. A study on the clinical trial guidelines of herbal medicinal drug, "Korean Institution of Oriental Medicine", Ministry of Food and Drug Safety, 01~ (2005)
  40. A Study on the clinical trial guideline of herbal medical drug(II), "Korean Institution of Oriental Medicine", Ministry of Food and Drug Safety, 11~ (2005)
  41. Research on outcome indicators for clinical trials of herbal medicinal products, "Industry-Academia Collaboration Foundation, KyungHee University", Ministry of Food and Drug Safety, ~ (2006)
  42. Ministry of Food and Drug Safety, "General considerations in clinical trials of herbal medicine preparations", Ministry of Food and Drug Safety, ~ (2007)
  43. National Institute of Food and Drug Safety Evaluation, "Quality guidelines of herbal medicine for clinical trial", ~ (2017)
  44. Kokudo N, "Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma : The Japan Society of Hepatology 2013 update(3rd JSH-HCC Guidelines)", Hepatol Res, 45, pp.123~127 (2015)
  45. Omata M, "Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma", Hepatol Int, 11(4), pp.317~370 (2017)
  46. Lim HS, "Malignant tumor Chinese medicine treatment guide", pp.371~399 (2014), People's medical publishing house
  47. Zhou J, "Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China", Liver Cancer, 7(3), pp.235~260 (2018)
  48. European Association for the Study of the Liver, "EASL Clinical Practice Guidelines : Management of hepatocellular carcinoma", J of Hepatol, 69(1), pp.182~236 (2018)
  49. Verslype C, "Hepatocellular carcinoma:ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 23(uppl 7), pp.vii41~vii48 (2012)
  50. Heimbach JK, "AASLD Guidelines for the Treatment of Hepatocellular Carcinoma", Hepatology, 67(1), pp.358~380 (2018)
  51. Marrero JA, "ACG clinical guideline : the diagnosis and management of focal liver lesions", Am J Gastroenterol, 109(9), pp.1328~1347 (2014)
  52. Chay WY, "Coriolus versicolor(Yunzhi)Use as Therapy in Advanced Hepatocellular Carcinoma Patients with Poor Liver Function or Who Are Unfit for Standard Therapy", J Altern Complement Med, 23(8), pp.648~652 (2017)
  53. Ye X, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain", J Pain Symptom Manage, 51(6), pp.979~986 (2016)
  54. Xu L, "Jian Pi Li Qi Decoction Alleviated Postembolization Syndrome Following Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma : A Randomized, Double-Blind, Placebo-Controlled Trial", Integr Cancer Ther, 15(3), pp.349~357 (2016)
  55. Zhong C, "Clinical study of hepatectomy combined with Jianpi Huayu Therapy for hepatocellular carcinoma", Asian Pac J Cancer Prev, 15(4), pp.5951~5957 (2014)
  56. Shimada M, "Effect of TU-100, a traditional Japanese medicine, administered after hepatic resection in patients with liver cancer : a multi-center, phase III trial(JFMC40-1001)", Int J Clin Oncol, 20(1), pp.95~104 (2015)
  57. Tian HQ, "Treatment of middle", late stage primary hepatic carcinoma by Chinese medicine comprehensive therapy : A prospective randomized controlled study, 2010, pp.16(2), 102~108
  58. Yinglu F, "A new way : alleviating postembolization syndrome following transcatheter arterial chemoembolization", J Altern Complement Med, 15(2), pp.175~181 (2009)
  59. Zhai XF, "Traditional Herbal Medicine Prevents Postoperative Recurrence of Small Hepatocellular Carcinoma : A Randomized Controlled Study", Cancer, 124(10), pp.2161~2168 (2018)
  60. Chen Q, "Effect of Huaier granule on recurrence after curative resection of HCC : a multicenter, randomized clinical trial", Gut, 67(11), pp.2006~2016 (2018)
  61. Wu GL, "Short-term Effect of Combined Therapy with Jinlong Capsule(金龙胶囊)and Transcatheter Arterial Chemoembolization on Patients with Primary Hepatic Carcinoma and Its Influence on Serum Osteopontin Expression", Chin J Integr Med, 16(2), pp.109~113 (2010)
  62. 정태영, "한방병원에서 치료받은 암환자 899명에 대한 임상적 특성 분석", 대한한방내과학회지, 31(1), pp.102~112 (2010), 대한한방내과학회
  63. Capussotti L, "Major liver resections for hepatocellular carcinoma on cirrhosis : early and long-term outcomes", Liver Transpl, 10(2 Suppl 1), pp.S64~S68 (2004)
  64. Lai EC, "Hepatic resection for hepatocellular carcinoma. An audit of 343 patients", Ann Surg, 221(3), pp.291~298 (1995)
  65. Yoo SH, "Complications Associated with Transcatheter Arterial Chemoembolization in Patients with Hepatocellular Carcinoma", Korean J of liver cancer study group, 11(2), pp.144~148 (2011)
  66. Kwak HW, "Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area", J Gastroenterol Hepatol, 29(4), pp.820~829 (2014)
  67. Yan JU, "Syndrome Differentiation and Treatment of Primary Hepatocellular Carcinoma in Traditional Chinese Medicine", Chinese Journal of Integrated Traditional and Western Medicine, 20(3), pp.189~191 (2010)
  68. Brierley J, "The principles of cancer staging", Ecancermedicalscience, 10, pp.ed61~ (2016)
  69. "Cancer Registration Learning Center"[URL]
  70. Montazeri A, "How quality of life data contribute to our understanding of cancer patients'experiences?A study of patients with lung cancer", Quality of Life Research, 12(2), pp.157~166 (2003)
  71. 조정효, "암 관련 삶의 질 평가도구에 관한 연구 현황", 대한한방내과학회지, 27(1), pp.84~91 (2006), 대한한방내과학회
  72. 최임순, "임상시험 시험대상자설명서의 가독성 평가", 한국임상약학회지, 26(1), pp.33~39 (2016), 한국임상약학회
  73. Caillet P, "Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer. ELCAPA study", J Clin Oncol, 29(27), pp.3636~3642 (2011)
  74. Evaluation of the safety information of the client requesting pharmaceutical clinical trials and considerations for reporting, "Ministry of Food and Drug Safety", ~ (2017)

관련 논문AI추천

한약을 사용한 암환자 대상 임상시험에서의 항암 효능 평가변수 고찰강민준, 박현석, 신원빈, 양운호, 여운석, 전천후대한예방한의학회 · 대한예방한의학회지2024 · 제28권 제1호Herbal Medicine for Liver Cancer: A Protocol for Systematic Review and Meta-Analysis권승원, 송가연, 양승보대한한방내과학회 · 대한한방내과학회지2022 · 제43권 제4호암 환자 대상 한의약 임상시험에서 변증 활용에 대한 분석고성규, 박선주, 신용철, 장보형, 전천후대한예방한의학회 · 대한예방한의학회지2015 · 제19권 제1호위암 치료에 대한 한의 임상 가이드라인문구, 김효린, 김효영, 백동기, 유화승, 장철용, 하예진대한한방내과학회 · 대한한방내과학회지2016 · 제37권 제1호위암의 중의약 치료에 대한 문헌적 고찰곽민아, 서정철, 손기철, 정진형대한한방내과학회 · 대한한방내과학회지2014 · 제35권 제3호단일 한방병원에 내원한 간암환자 60명에 대한 임상적 특징 분석; 후향적 차트 리뷰김경순, 김상찬, 김승모, 윤미정, 조나경, 최홍식대한한방내과학회 · 대한한방내과학회지2020 · 제41권 제3호

이 간행물의 다른 논문 (10건)

수컷 생쥐의 골다공증과 근위축에 대한 益智仁의 효과안상현, 박선영, 김형준pp. 1-12비알콜성 지방간질환의 한방치료에 대한 체계적 문헌고찰최홍식, 이유리, 조나경, 김경순, 김승모pp. 13-37비알코올성 지방간질환의 利水 약재 포함 한약 치료에 대한 최신 임상 연구 동향 - CAJ 검색을 중심으로조명재, 김영광, 문영호pp. 38-57한수대보원이 포유동물인 생쥐 모델에서 골 손실 및 RANKL 유도 파골세포 분화에 미치는 영향전찬용, 장시성, 류홍선, 황귀서pp. 58-69췌장암에 대한 국내 한의학 연구 동향 고찰 - 국내 한의학 논문을 중심으로 -김성수, 정하영, 박은주, 이아름, 이준명, 성신, 한가진pp. 70-88
원문 보기